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Background: Cardiac myosin regulatory light chain (RLC) phosphorylation alters cardiac muscle function.
Results: Phosphorylation affects mechanical parameters of cardiac muscle contraction during shortening.
Conclusion: Phosphorylation impacts mechanical function of cardiac muscle and is altered during cardiac disease.
Significance: Understanding RLC regulation by phosphorylation in cardiac muscle contraction is crucial for understanding
changes in disease.
Understandinghowcardiacmyosin regulatory light chain (RLC)
phosphorylation alters cardiac muscle mechanics is important
because it is often altered in cardiac disease. The effect this protein
phosphorylation has on muscle mechanics during a physiological
range of shortening velocities, during which the heart generates
power and performs work, has not been addressed. We have
expressed and phosphorylated recombinant Rattus norvegicus left
ventricular RLC. In vitro we have phosphorylated these recombi-
nant species with cardiac myosin light chain kinase and zipper-
interacting protein kinase.We compare rat permeabilized cardiac
trabeculae,whichhave undergone exchangewith differently phos-
phorylated RLC species. We were able to enrich trabecular RLC
phosphorylationby 40%comparedwith controls and, in a separate
series, lower RLC phosphorylation to 60% of control values. Com-
paredwith the trabeculaewith a low level of RLCphosphorylation,
RLC phosphorylation enrichment increased isometric force by
more than 3-fold and peak power output by more than 7-fold and
approximately doubled both maximum shortening speed and the
shortening velocity that generated peak power. We augmented
these measurements by observing increased RLC phosphoryla-
tion of human and ratHF samples from endocardial left ventric-
ular homogenate. These results demonstrate the importance of
increased RLC phosphorylation in the up-regulation ofmyocar-
dial performance and suggest that reduced RLC phosphory-
lation is a key aspect of impaired contractile function in the
diseased myocardium.
Interactions between the two contractile proteins actin (thin
filament) and myosin (thick filament) drive the contractile
machinery of muscle contraction (1). The molecular mecha-
nisms by which these proteins are regulated in cardiac muscle
contraction are still yet to be understood fully (2). Thin filament
activation by Ca2 binding to the troponin-tropomyosin com-
plex is known to be important in normal cardiac contraction
and in the dysfunction of contractile characteristics in heart
failure (HF)2 (3). In contrast, thick filament proteins have less
defined roles in regulation of cardiac contraction (4, 5).
Evidence suggests that myosin-associated regulatory pro-
teins, such as the cardiac ventricular isoform of the regulatory
light chain (RLC), have an influential role to play in muscle
contraction mediated by phosphorylation (6–13). In vitro studies
performedbyStull etal. (4)have shownacorrelationbetweenRLC
phosphorylationand isometric forceof twitchpotentiation inskel-
etalmuscle.This suggested thatCa2binding to troponinC(TnC)
is not the only process that regulates striated muscle contraction.
Furthermore, in vitro and structural studies have implicated the
negative charge associated with phosphorylation of the RLC to
structurally repel myosin heads away from the thick filament
toward actin (14–16). There is also evidence that RLC phospho-
* This work was supported, in whole or in part, by National Institutes of
Health, NHLBI Grant HL004232 12. This work presented herein was also
supported by Wellcome Trust Grants 091460/Z/10/Z, 092852/Z/10/Z,
092852/Z/10/Z, Biotechnology and Biological Sciences Research Council
Grant BB/I019448/1, and The British Heart Foundation (to M.-C. L., S. B. M.,
and M. A. F.).
Author’s Choice—Final version full access.
1 To whom correspondence should be addressed: Lee Kong Chian School of
Medicine Nanyang Technological University, RTP Level 4, 50 Nanyang Dr.,
Singapore637553. Tel.: 65-6592-3172; Fax: 65-6515-0417; E-mail:m.ferenczi@
ntu.edu.sg.
2 The abbreviations used are: HF, heart failure; FV, force-velocity; MI, myocardial
infarction; NYHA, New York Heart Association; PV, power-velocity; RLC, regu-
latory light chain; rRLC, recombinant regulatory light chain; TnC, troponin C.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 288, NO. 19, pp. 13446–13454, May 10, 2013
Author’s Choice Published in the U.S.A.
13446 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288•NUMBER 19•MAY 10, 2013
 at Im
perial College London on January 28, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
rylation may affect stiffness of the myosin lever arm (17) and/or
hinge region in smoothmuscle (18).
Furthermore, pathological mutations to the RLC in humans
are known to present as familial hypertrophic cardiomyopa-
thies. Many of these mutations occur in and around the phos-
phorylatable region of the RLC and can affect the ability of the
RLC to be phosphorylated, as seen in the E22Kmutation among
others (12, 19, 20). Evidence also exists to suggest RLC hyper-
phosphorylation could drive hypertrophy (21).
Studies have been performed to elucidate RLC phosphoryla-
tion mechanisms; genetic mutant murine models of disease
have been used, either replicating mutations found in human
patients or creating mutant RLCs that are unphosphorylatable
to assess calcium sensitivity changes (19, 22–26). Others have
dephosphorylated RLC in cardiac preparations using 2,3-bu-
tanedione monoxime, which has unknown protein dephos-
phorylation specificity (14). These studies elucidated the effect
amutation has on cardiac pathology frommodel organisms but
did not isolate the effect of RLC phosphorylation on muscle
mechanics independent of other protein modifications. These
studies did not assess mechanics during muscle shortening.
In this paper, a Phos-tagTM SDS-PAGE method was utilized
to observe the changing RLC phosphorylation profile during
heart failure progression in human patients in New York Heart
Association (NYHA)-classified HF progression and in a rat
model of chronic MI, which manifests as early cardiac hyper-
trophy and eventual heart failure.
In addition, we studied and evaluated the mechanical effect
of RLC phosphorylation on permeabilized cardiac tissue. We
used force-velocity (FV) and power-velocity (PV) relationships
to assess the effect a physiological range of RLC phosphoryla-
tions had on the contractile characteristics of permeabilized
cardiac trabeculae. This was performed duringmuscle shorten-
ing over a set of velocities in which the heart generates power
and performs work in the physiological range.
EXPERIMENTAL PROCEDURES
Rat MI Model—All animal surgical procedures and periop-
erative management were carried out in accordance with the
Guide for theCare andUse of LaboratoryAnimals published by
theUnited States National Institutes of Health under assurance
number A5634-01. Adult male Sprague-Dawley rats (250–300
g) underwent proximal left anterior descending coronary liga-
tion to induce chronic myocardial infarction as described pre-
viously (27). Following 4 or 16 weeks, rats were sacrificed by
cervical dislocation. Age-matched controls were used as a com-
parisonwith twoMI time points, 4weeks post-MI and 16weeks
post-MI. Relative hypertrophy was assessed by heart weight to
body weight ratio, and ejection fraction was measured by
M-mode echocardiography (Vevo 770, Visualsonics) to give a
measure of cardiac function (Table 1).
Myofibril Collection—10mgof ratmyocardiumwas removed
from the left ventricular endocardial region close to the apex,
frozen in liquid nitrogen, and stored at 80 °C. On the day of
the experiment, samples were mechanically homogenized
using a pestle and mortar cooled with dry ice. Samples were
then added to SDS-PAGE sample buffer. Human tissue samples
were also removed from the endocardial layer of the left ventri-
cle and prepared the same way. Porcine hearts were obtained
from the Royal Veterinary College. These were rinsed in ice-
cold saline and prepared for gel analysis in the same manner as
rat and human myofibrils.
RLC Protein Phosphorylation Determination—Samples were
heated at 95 °C for 2 min to aid protein denaturation. Gels
were subsequently loaded with 10-l individual samples.
Phos-tagTM incorporating 15% SDS-PAGE and PVDF mem-
brane blotting with chemiluminescent antibody detection were
used to ascertain quantitative RLC phosphorylation levels. Gels
were run for 120 min and blotted for 60 min. Membranes were
probed with mouse anti-RLC antibodies (F109.3E1, Alexis Bio-
chemicals, Nottingham, UK). Goat anti-mouse horseradish
peroxidase (HRP)-linked IgG was used with a Bio-Rad electro-
chemiluminescence kit for band visualization in a Bio-Rad
GelDoc imager. ImageJ was used to threshold and measure
individual band densities.
Cloning and Expression of Recombinant RLC (rRLC)—rRLC
was expressed from pET6a vector fused to an N-terminal histi-
dine tag and tobacco etch virus protease site. After expression,
cells harvested by centrifugation (10 min, 5000 g) were lysed
by BugBuster MasterMix (71456-4, Novagen) containing
EDTA-free protease inhibitor mixture (11873580001, Roche
Applied Science), and the inclusion bodies were purified
according to the manufacturer’s instructions. The purified
inclusion bodies were resolubilized in IMAC binding buffer (25
mM HEPES, 500 mM NaCl, 1 mM MgCl2, 1 mM DTT, 20 mM
imidazole) containing 6 M urea for 4 h at 4 °C under vigorous
stirring. After removing insoluble components by centrifuga-
tion at 15,000 g for 30 min, the supernatant was applied to a
5-ml HisTrap FF column (GE Healthcare) with a flow rate of
1–2 ml/min. The column was washed with 20 column volumes
of IMAC binding buffer containing 6 M urea, and the protein
was eluted with a step gradient of imidazole (50–500 mM, 50
mM increments) in IMAC binding buffer containing 6 M urea.
Fractions containing purified protein were pooled, and urea
were removed by dialyzing three times against dialysis buffer
(25 mM HEPES, 250 mM NaCl, 1 mM MgCl2, 1 mM DTT). To
remove the N-terminal histidine tag, tobacco etch virus prote-
ase was added in a 1:100 stoichiometry, and the protein was
digested overnight at 4 °C. The sodium chloride concentration
was adjusted to 500 mM, and tobacco etch virus proteases and
remaining impurities were removed by passing through 1-ml
HisTrapFF (GE Healthcare) columns. The column flow-through
containing the purified rRLC was collected, and the protein was
concentrated to 2mg/ml (UFC901024,AMICONspin concentra-
tors). Protein was stored at80 °C until further use.
RLC Phosphorylation—rRLC phosphorylation species from
Rattus norvegicuswere created by incubation of rRLCwith car-
diac myosin light chain kinase donated by Mathias Gautel
(King’s College London) and zipper-interacting protein kinase
(28) (Invitrogen) at 37 °C for 120 min in a kinase buffer (25 mM
HEPES, 200 mM NaCl, 1 mM MgCl2, 1 mM DTT, 5% glycerol,
and 200 M ATP). Fresh kinase (1 g/ml of reaction mixture)
was added to the reaction mixture every 30 min. Kinases and
phosphatases were removed by molecular weight cut-off col-
umn filtration. Phosphorylated rRLC was mixed 50:50 with
unphosphorylated rRLC to produce control-mimicking in vivo
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RLC phosphorylation. Dephosphorylated rRLC was produced
by incubation with shrimp alkaline phosphatase (Fermentas)
(20 units/100 l of protein) in vitro for 60 min in kinase buffer
without ATP.
RLC Labeling and Exchange—Following expression, the
buffer solution (25 mM HEPES, pH 7.1) containing recombi-
nant RLC was exchanged to a labeling buffer (0.1 M NaCl and
0.1 M NaH2PO4 at pH 7.2) using PD-10 columns (GE Health-
care). Protein was subsequently incubated on ice for 2 h with
N-hydroxysuccinimide-rhodamine ester (10 mg/ml in DMSO;
Thermo Scientific). Excess dye was removed using ZebaTM
desalting spin columns (Thermo Scientific). Absorbance at 555
nm for the protein dye conjugate was used to indicate the label-
ing ratio of dye to protein. The buffer was changed to 5 mM
ATP, 5 mM EGTA, 5 mM EDTA, 10 mM imidazole, 150 mM
potassium proprionate, 10 mM KH2PO4, 5 mM DTT, and 0.5
mM trifluoperazine at pH 6.5 (exchange solution) for protein
exchange as previously described (29–31). Explanted, permea-
bilized, and T-clipped trabeculae were mounted between two
hooks at a sarcomere length of 2.1 m and cooled in relaxing
solution to 0.5 °C. Trabeculae were moved to a stage at 20 °C to
be incubated for 45 min in 0.5 mg/ml RLC exchange solution,
which incorporated 0.5 mg/ml TnC. TnC was added to all
exchange solutions to reintroduce TnC that is lost during
exchange so as not to alter contractile characteristics of the
preparations. Trabeculae were incubated in three sequential
15-min incubations with fresh 30-l drops of RLC exchange
solution incorporating TnC. The preparation was then washed
three times (15min each, at 0.5 °C) in relaxing solution contain-
ing 0.5 mg/ml TnC to remove unbound RLC.
Force-Velocity Protocol—Trabeculae were mounted in relax-
ing solution between hooks attached at one end to a force trans-
ducer (AE801, HJK Sensoren Systeme, Freidburg, Germany)
and at the other to a motor (32). Shellac dissolved in ethanol
was used to fix the trabecular tissue in place. Sarcomere length
was set to 2.1 m using diffraction of helium-neon laser light
(633 nm) to visualize the first order diffraction pattern spacing.
Trabeculae were taken through a sequence of solution changes
using a two-stage quartz-surfaced platform system that was
temperature-controlled (2 or 20 °C) and moved horizontally
using a stepper motor (33). Each platform had two pedestals,
which carried 30 l of solution on their surface. The platform
wasmoved so that the trabecular tissue was submerged in these
bubbles of solutions in the following order: preactivating (2 °C),
activating (2 °C), activating (20 °C), and relaxing (20 °C) repre-
sentative tension trace shown in Fig. 1A. Trabecular dimen-
sions were recorded by observation with transmitted light with
a 40 objective (0.75 numerical aperture, water; Zeiss). The
stage movements and trabecular lengths were controlled using
LabView software that also recorded digitized motor and force
transducer outputs during experimentation. Upon activation
and after peak isometric force was attained, “slack test” meas-
urements on each preparation were carried out. Trabeculae
were slackened by rapidly reducing length to between 8 and
12% of the initial muscle length. This was performed three
times with each fiber. The time of force deviation from “slack
force” was determined by fitting through the initial 100 ms of
the tension recovery trace. The time taken for force to rise
above the zero-force level was measured in each case by fitting
the initial linear phase of tension development post-slack (Fig.
1B, green lines). Vmax was calculated from the slope of the line
joining the data points resulting from a plot of step length
amplitude versus slack time (34). The order in which the slack
lengthswere appliedwas randomized. FVmeasurements incor-
porated release/ramp protocols (35) with ramp velocities
between 0.1 and 1.5 muscle lengths/s. The ratio of muscle
length in the ramp and in the release is dependent on the veloc-
ity of the ramp to achieve an isotonic plateau during the proto-
col. In our experiments, a rapid release of 8% of initial muscle
length was applied (Fig. 1, C and D). The rapid release compo-
nent effectively slackens the parallel elastic component of the
preparation, giving rise to a nearly steady force level during
ramp shortening.
Force-Velocity Relationships—Force measurements were
normalized to trabecular cross-sectional area and reported as
kilonewtons/m2.Vmax is reported inmuscle lengths/s. For each
trabeculum, the relationship between force during shortening
and shortening velocity was fit to a hyperbola previously
described by Hill (36). The parameters from these fits are pre-
sented as means S.E.
Statistics—Two-way analysis of variance was used to make
multiple comparisons between treatment groups in Table 1. For
other analyses, one-way analysis of variance was used to test our
experimental hypotheses. Appropriate post hoc pairwisemultiple
comparisonsweremadeusing aBonferroni adjusted t testmethod
with an overall significance of p 0.05 in all instances.
RESULTS
Phos-tagTM gel electrophoresis was used to evaluate RLC
phosphorylation levels during progression of a rat heart failure
model caused by left anterior descending coronary artery liga-
tion. A phosphorylation level of 0.53  0.06 mol of Pi/mol of
RLC (n 12) was observed in tissue from the inner left ventric-
ular wall of the rat, in comparison with the phosphorylation
level in non-failing human myocardium (0.41  0.05 mol of
Pi/mol of RLC (n 5)). These values are very similar to that of
the pig left ventricular wall at 0.42 0.02 mol of Pi/mol of RLC
(n  2). Left ventricular RLC phosphorylation during the
hypertrophic remodeling phase post-MIwas 0.72 0.03mol of
Pi/mol of RLC (n  5) versus healthy rat at 0.53  0.06 mol
Pi/mol of RLC (n 12), and this difference was assessed as the
model progressed to chronically dilated and failing phenotype
(0.76 0.07 mol of Pi/mol of RLC (n 4), p 0.05), showing a
significant difference in late stage disease.
In addition, the RLC phosphorylation levels during progres-
sion of clinical heart failure in human patients as defined by
symptomatic classification of severity (the NYHA classifica-
tion) were evaluated. A similar trend of increased RLC phos-
phorylation during disease was found when we studied human
heart failure tissue during progressive clinically designated dis-
ease severity. Those classified NYHA I and II show a similar
trend, increasing during disease progression from a control
phosphorylation state of 0.47 0.05mol of Pi/mol of RLC (n
4) to NYHA III and IV patient tissues, which show a significant
increase, 0.6 0.03 mol of Pi/mol of RLC (n 4) (p 0.05) in
comparison (Fig. 2).
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In order to study the effect of RLC phosphorylation under
more controlled conditions, cardiac RLCwas expressed in bac-
teria. The phosphorylation levels of the RLC were increased by
incubation with cardiac myosin light chain kinase and zipper-
interacting protein kinase. ThePhos-tagTMgels indicated that a
total of1mol of Pi/mol of RLC is incorporated into theRLCby
this treatment. Another fraction of the expressed RLC was incu-
bated with the nonspecific phosphatase shrimp alkaline phospha-
tase to ensure that all RLC species were dephosphorylated.
These RLCs could be exchanged into skinned rat trabeculum
fibers to replace the exogenous RLCs. Exchange treatments to
mimic the “endogenous” levels used a mixture of the in vitro
phosphorylated and dephosphorylated light chains to achieve a
total phosphorylation level of 0.5 mol of Pi/mol. A “reduced”
phosphorylation level was achieved by exchange of the dephos-
phorylated RLC alone, and an “increased” RLC phosphoryla-
tion level was achieved by using the phosphorylated RLC frac-
tion for the exchange. These differently phosphorylated rRLC
species were compared with endogenous trabecular RLC
“native” phosphorylation (Fig. 3).
Fluorescently labeled RLC was exchanged into permeabi-
lized trabecular muscle preparations to visualize the spatial
incorporation of these recombinant RLC species into the sar-
comeric network. Fig. 4A shows a three-dimensional z stack
reconstruction of the surface of a cardiac trabeculum that has
undergone exchange with rhodamine-labeled RLC. We show
specific localization of recombinant labeled RLC to themyosin-
containing A-band region, and only background levels of fluo-
rescence in the myosin-lacking I-band regions (Fig. 4B). The
A-band region was measured as 1.69 0.05m at a sarcomere
FIGURE1.A, representative tension traceduring a temperature jumpactivationbetween0.5 and20 °Cof a permeabilized trabeculum. Force rises to a isometric
plateau. 3 s after the temperature jump, the muscle is rapidly released and shortened at a fixed velocity for 50 ms, and then force recovers at the shortened
sarcomere length. Muscle is then restretched to the original length and relaxed in a low calcium solution at 4 s. B, tension traces during two slack test (ST)
measurements encompassing a 10% rapid release (black trace) and 12% rapid release (red trace). Time zero (T 0) is reset tomark the time of the onset of the
release. The time taken for tension to deviate from zero “slack force” (F 0) in each slack length test is used to calculate peak unloaded shortening velocity
(Vmax). Shown are tension traces during a range of fixed velocities (C) and the correspondingmotor traces showing the release lengths and ramp velocities of
each maneuver (D). kN, kilonewtons.ML, muscle lengths.
TABLE 1
Rat model of myocardial infarction shows compensated hypertrophy at 4 weeks with decompensation by 16 weeks
Heartweight/bodyweight ratios reveal a hypertrophic response at both time points comparedwith controls, although it is significantly greater at 4weeks. Echocardiography
reveals a reduced ejection fraction at both time points compared with controls, but it is further reduced by 16 weeks compared with 4 weeks post-MI. Numeric values for
ejection fraction and heart weight/body weight ratios are stated as mean  S.E. with n numbers accompanying each value. HW/BW, heart weight/body weight; AMC,
age-matched control.
Ejection fraction HW/BW
AMC MIa AMC MI
4 weeks 78.6 3.89 (n 9) 43.3 3.89 (n 9) 3.43 0.17 (n 9) 4.84 0.17b (n 9)
16 weeksc 74.5 4.12 (n 8) 30.9 3.89 (n 9) 2.85 0.18d (n 8) 3.43 0.17e (n 9)
a Significant main MI treatment effect (p 0.001).
b Significant MI effects, within 4-week pairing (p 0.001).
c Significant main recovery time effect (p 0.046).
d Significant recovery time effect within AMC pairing (p 0.023).
e Significant MI effect within 16-week pairing (p 0.024) and significant recovery time effect within MI pairing (p 0.001).
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length of 2.25  0.02, consistent with literature values for
A-band length (n  3) (37, 38). Exchange efficiency was ana-
lyzed in skinned trabecular samples by performing a secondary
exchange with unlabeled recombinant RLC as a “washout” pro-
tocol for fluorescently labeled RLC species. Fig. 4B presents an
example of fluorescence intensity profile across many sarcom-
eres showing a significant fluorescence decrease after the sec-
ondary exchange with unlabeled RLC. 50% exchange efficiency
was evaluated (Fig. 4C) by comparing pre- and post-washout
fluorescence profiles. This allowed the estimation of RLC
phosphorylation state postexchange for trabeculae treated
with enriched or dephosphorylated recombinant RLC spe-
cies (Fig. 4D).
Postexchange Vmax values (derived from slack tests) and
force measurements at different release velocities were com-
bined to determine the FV relations (see Fig. 1) for each group
of trabeculae (dephosphorylated, enriched phosphorylation,
control). Control-exchanged trabeculae were compared with
untreated trabeculae to assess the effect of RLC exchange (Fig.
5, A and B). These two groups did not show significant differ-
ences in most parameters (Table 2). However, the curvature of
Hill’s hyperbolic fit (a/Po) of the FV relations was affected by
control exchange. Control exchange showed a 2-fold increase
in the a/Po parameter (p 0.05).
RLC phosphorylation state most clearly altered the force,
power, and Vmax of trabeculae (Table 2 and Fig. 6). Mean force
and power in the enriched RLC phosphorylation trabeculae
were 3.7- and 7.5-fold higher, respectively, than mean force
and power in the reduced phosphorylation series (p  0.005).
Average Vmax was 66% higher in the phosphorylation-en-
hanced trabeculae compared with the reduced phosphoryla-
tion state (p 0.02). Themultiple-comparison statistical mod-
els did not always yield significant differences between the
control group, which consisted of a 50:50 dephosphorylated/
phosphorylated exchange mixture, and the reduced and
enhanced phosphorylation groups (Table 2). For instance,
power output in the phosphorylation-enriched group wasmar-
ginally different from the peak power observed in the control
and native phosphorylation groups (0.08  p  0.04). The
velocity at which peak power occurred (VPP) showed a similar
pattern; VPP in the enhanced phosphorylation group was
2-fold faster than in the reduced phosphorylation state (p 
0.012) and showed amarginal difference from the “native” control
(p 0.04). Themean force, power, andVmax for the 50:50 control
exchange serieswere consistently intermediate to the reduced and
enhanced phosphorylation groups (Figs. 6 and 7). RLC phospho-
rylation state seems to be a key regulator of a continuum of phys-
iologically relevant aspects of cardiac performance.
DISCUSSION
In this study, we have evaluated the effect that altering cRLC
phosphorylation has on cardiacmusclemechanics.We observe
clearmodulation of cardiacmuscle function by RLC phosphor-
ylation. The alteration of many mechanical properties in our
experiments provides evidence that RLC phosphorylation state
is an important modulator of the behavior of cardiac muscle in
health and disease.
It is known that RLC phosphorylation does not change sig-
nificantly between systolic and diastolic states (39), but changes
to phosphorylation may accompany cardiac fitness, pathology,
and/or age. We have shown a dramatic increase in RLC phos-
FIGURE 2. Top, SDS-PAGE Phos-tagTM analysis of cRLC phosphorylation level in
mol of phosphate/mol of cRLC. cRLC phosphorylationwasmeasured in left ven-
tricular tissue from porcine, human, and rat samples. Samples from human left
ventricular tissue taken frompatientswere categorizedasmoderate (NYHA Ior II
(n 5)) or severe heart failure (NYHA III or IV (n 5)) or normal donor (Human
Non-failingLV,n5).Normal rat leftventricular tissue(HealthyRatLV,n12)was
compared with rat LV 4 weeks post-chronic MI (Rat post-MI LVH, n 5) and 20
weeks post-chronic MI (Rat post-MI HF, n 4). All data are displayed asmean
S.E. (error bars). *, significance of p 0.05 comparedwith control. Bottom, repre-
sentativeWesternblots showing the ratioofphosphorylationand theamountof
phosphorylation sites in each organism. Arrow, direction of blot. 2P, 1P, and 0P,
the number of RLC sites phosphorylated for each band.
FIGURE 3. A, bar plot indicating the phosphorylation level of differently phos-
phorylated rat rRLC species generated by incubation with kinases (Enriched),
shrimp alkaline phosphatase (Reduced), or a mixture of the two mimicking
native RLC phosphorylation levels (Control). Native trabecular phosphoryla-
tion level is displayed for comparison (Native). All data are plotted asmean
S.E. (error bars), and n values are given for each preparation. B, representative
Western blots of differently phosphorylated rRLC species. Arrow, direction of
blot. 2P, 1P, and 0P, number of RLC sites phosphorylated.
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phorylation in both a model of chronic myocardial infarction
in rats and during the progression of NYHA-categorized HF
in human myectomy samples (Fig. 2). We demonstrate a
correlation between phosphorylation change of the RLC and
cardiac performance that is conserved between rat and
human cardiac tissue during HF progression. This observa-
tion is complementary to the evidence that RLC phosphoryl-
ation can drive cardiac hypertrophy (21). Reductions in RLC
phosphorylation due to RLC mutations, expression of non-
phosphorylatable RLC, or during human heart failure are
also observed (12, 13, 19, 20, 22, 25, 26, 40–42). Interest-
ingly, decreases in RLC phosphorylation have been observed
when the catalytic subunit of the type 1 protein phosphatase
 isoform (PP1c) first identified by Nishio et al. (43) and
MYPT2 (regulatory subunit) have been transferred into neo-
natal cardiomyocytes, which coincided with blocked sar-
comere organization (43, 44). PP1c activity stimulated by
overexpression of MYPT2 showed decreased basal RLC
FIGURE 4. A, confocal image of a permeabilized cardiac trabeculum after exchange with a recombinant fluorescently labeled rRLC. B, fluorescent intensity
across sarcomeres measured before and after a secondary exchange with an unlabeled recombinant RLC. C, exchange efficiency calculated from integrating
fluorescent intensity before and after secondary exchange. Data presented are an average S.E. of n 3 separate exchange procedures on permeabilized
trabeculae.D, calculated RLC phosphorylation changes after trabeculae have undergone exchangewith differently phosphorylated rRLC species. Control, the
native left ventricular phosphorylation level of RLC (n  12). Control Exchange, the calculated phosphorylation level of trabeculae that have undergone
exchange with rRLC that is similarly phosphorylated to native RLC. Enriched RLC Phos, the RLC phosphorylation after exchange with enriched rRLC species.
Depleted RLC Phos, the effect on trabecular phosphorylation after exchange with dephosphorylated rRLC species. Error bars are calculated from S.E. values of
exchange efficiencies.
FIGURE 5. A, FV relationships of untreated trabeculae (n 8) compared with trabeculae that have undergone control exchange (n 6) with rRLC species of
similar to native levels of RLC phosphorylation. Forcewasmeasured during the plateau phase for the individual fixed shortening velocity. Relations are fit with
Hill’s hyperbolic equation. All points aremeans of force produced during shortening S.E. (error bars). B, PV relations calculated fromFV relations of untreated
trabeculae (n 8) compared with control exchange (n 6). All data are presented as power S.E. This fitting procedure fits the relationship between force
during shortening and shortening velocity in muscle lengths (ML)/s. Microsoft Excel solver was used to minimize the sum of the squared error between
observed and expected values of force. The Vmax measurements obtained by the slack test method constrain the fitting procedure.
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phosphorylation, reduced contractility, and a phenotype of
left ventricular hypertrophy (45).
However, it is important to note that human and rat RLCs are
different. Human RLC comes as two distinct charge variants
with identicalmolecularweight, denoted as LC-2 andLC-2* (8).
The LC-2 isoform is more highly expressed (70% LC-2/30%
LC-2*) and more highly phosphorylated (8, 41). This ratio of
expression does not often seem to alter during disease (8).
Therefore, human ventricular tissue exists as three different
myosin isoenzymes (LC-2/LC-2, LC-2/LC-2*, and LC-2*/LC-
2*). This does not hold true for rats, where one ventricular iso-
form of RLC is evident and the three isoenzymes are formed as
mixtures of  and  myosin heavy chains (46). These human
ventricular RLCs possess single serine phosphorylation sites,
whereas the single rat ventricular isoform of RLChas two phos-
phorylatable sites (11, 26, 47). The possible function of this
second site is so far unknown. It would certainly be of interest to
know the effect that the second phosphorylation site has on
myosin structure and function, specifically whether this second
site is complementary to the function of the first. The relation-
ship between RLC phosphorylation change and cardiac per-
formance that we observe in myectomy samples and in our rat
model is conserved in our human samples, suggesting that
phosphorylation has a similar role, whether RLC is mono- or
diphosphorylated. Interestingly, diphosphorylated RLC species
are present in animals in which -cardiac myosin heavy chain
predominates and where the heart rate is fast. Species with pre-
dominance toward -cardiac myosin heavy chain and lower
heart rates possess a single phosphorylatable site and two ven-
tricular RLC isoforms.
The exact role of RLC as a modulator of cardiac muscle and
themechanisms by which it is regulated have been debated (39,
48). Indirect evidence provided by electron microscopy and
optical diffraction studies have supported the hypothesis that
RLC phosphorylation alters the disposition of myosin heads by
charge repulsion away from the thick filament (14–16, 49). The
TABLE 2
Numeric values of parameters from FV and PV fits
All values are displayed as mean S.E.
Enriched
(n 8)
Control
(n 6)
Native
(n 8)
Dephosphorylated
(n 5)
Peak isometric force (kilonewtons/m2) 81.9 10a 79.9 11 86.2 9a 22.3 7
Vmax (muscle lengths/s) 8.85 0.7a 6.33 0.9 7.01 0.7 5.34 0.4
a/Po 0.16 0.06 0.1 0.02 0.04 0.01 0.07 0.02
Power (kW/m3) 38.9 8a,b 17 3 14.7 4 5.13 3
Velocity at peak power (muscle lengths/s) 1.97 0.2a,b 1.36 0.1 1.03 0.2 0.9 0.2
a Different from dephosphorylated (0.02 p 0.001).
b Different from native (p 0.05).
FIGURE 6. A, FV relationships of trabeculae that have undergone exchange with rRLC species that are hyperphosphorylated (n 8), have control phosphory-
lation similar to native RLC phosphorylation (n  6), and are dephosphorylated (n  5). B, calculated PV relationships of trabeculae that have undergone
exchange with the three species of rRLC phosphorylation. All data are plotted as mean S.E. (error bars).ML/s, muscle lengths/s.
FIGURE 7. Parameters fromhyperbolic fits of FV and PV relationships plotted asmean S.E. (error bars) by RLC phosphorylationmagnitude normal-
ized to control phosphorylation.All parameters that had significant differences between phosphorylation statuseswere plotted: power (A), velocity at peak
power (B), and peak unloaded shortening velocity (Vmax) (C). All data sets were described with a linear fit.
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use of isolated myosins highlights a second hypothesis that
involves the elasticity of the lever arm region, whereby phos-
phorylation increases stiffness, increasing the myosin duty
cycle (17, 18). As of yet, the direct effect of cRLC phosphoryla-
tion on cardiacmuscle performance during shortening at inter-
mediate velocities where the muscle is performing mechanical
work has not been studied. Only Vmax and peak isometric force
have been evaluated (50–53), and the results are similar to
those observed in the present study.
We show thatwe can alterRLCphosphorylationwith theuse of
kinases (cardiac myosin light chain kinase and zipper-interacting
proteinkinase) in vitro (Fig. 3) andexchange thesephosphorylated
species intopermeabilizedcardiacpreparations toalterRLCphos-
phorylation (Fig. 4). Importantly, the alterations to phosphoryla-
tion we have made are within the range of the phosphorylation
changes observed during disease. We observed up to 0.8 mol of
Pi/mol of RLC in failing ratmyocardiumand increasedRLCphos-
phorylation in our experimental treatments to0.7mol of Pi/mol
of RLC. Previously reported RLC phosphorylation in disease phe-
notypes canbecompletely abolishedandsignificantly reduced (12,
19, 20, 54, 55). We have reduced phosphorylation significantly to
0.2 mol of Pi/mol of RLC.
We show that our exchange protocol used to replace native
cRLC with rRLC did not affect the FV and PV relations of the
trabecular preparations (Table 2 andFig. 5), demonstrating that
the RLC exchange protocol had little effect on the mechanical
function of the permeabilized trabeculae.Hence, our results are
fully accounted for by the altered RLC phosphorylation.
The range of differently phosphorylated RLC preparations
showed large changes to force and power during shortening
when compared with control (Fig. 6). Interestingly, a doselike
response of RLC phosphorylation affected many mechanical
parameters, such as the velocity at which peak power was
attained (VPP), Vmax, and power (Fig. 7). Clearly, RLC phos-
phorylation level affects the ability of cardiacmuscle to produce
power during shortening that is not only a calcium sensitivity
effect (19, 22–24) because these effects are demonstrated in
saturating 32 M [Ca2].
To our knowledge, the effect of RLC phosphorylation during
shortening at intermediate, work-producing velocities has not
been studied, and hence power production by the myocardium
has not been assessed. The power produced during shortening
is an important factor to study because it can be related to
cardiac muscle function at different heart rates. Our observa-
tions together with these early findings define two distinct roles
for RLCphosphorylation: 1) the inability of the RLC to be phos-
phorylated is a driver for cardiac pathology; 2) increases in RLC
phosphorylation may signify a compensatory adaptation to
pathology in certain instances.
Our results complement others that suggest that cardiac dis-
ease progressionmay be driven by an inability to phosphorylate
RLC appropriately. Here we extend the role of RLC phosphor-
ylation in pathophysiology to acquired heart failure post-MI,
with confirmation in myocardial samples from patients with
advanced heart failure and an animalmodel of chronicMI in rats.
Thus, increased RLC phosphorylationmay act as amechanism to
compensate for the loss of myofilamentmechanical power gener-
ation during progression of the failing myocardium.
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